OCTOBER 2013
Transactions
129
GSG aSSEt GMBH & co. vERWaLtUnGS KG’S (oRco-GSG) StRUctURaL
oPtIMISatIon oF tHE > € 400 MIo. REaL EStatE PoRtFoLIo
Gehrke Zumbroich & Partner has advised GSG asset GmbH & co. verwaltungs KG (oRco-GSG) with regard to the structural optimisation of its real estate portfolio. With approx. 815,000 sqm oRco-GSG is a leading provider of office- and commercial spare in Berlin. the portfolio comprises space between 20-20.000 sqm for production, office, workshop or storage. the formerly state owned oRco-GSG has been acquired from Land Berlin in 2007 in the course of a privatization by a joint venture of oRco Property Group and Morgan Stanley.
After a refinancing agreement for EUR 269,6 million. could be signed inter alia with the assistance of Gehrke Zumbroich & Partner in December 2012 with a banking club of five German banks, Gehrke Zumbroich & Partner now ad- vised the company in a complex transaction, which comprised the transfer of the complete real estate portfolio to several subsidiaries, especially to fa- cilitate future refinancing.
The team of Gehrke Zumbroich & Partner, which advised ORCO-GSG in the complete transaction, was led by Matthias Gehrke, naming partner of the firm.
Gehrke commented: “Already in the end of 2012 the refinancing of the expired € 304 mio. RBS loan agreement has been closed successfully. Now, the also successfully closed restructuring allows ORCO-GSG to focus only on the operative business for several years. The privatisation of the former land owned GSG has already been a success story. This may, now, continue and we are proud having supported our client in this regard.” LM
! ! !
SoHo FLoRdIS IntERnatIonaL acqUIRES PRotHERa
Soho Flordis International (SFI), an international provider of clinically proven natural medicines, announced recently the acquisitions of Ginsana and Prothera.
Ginsana from Pharmaton, is a Swiss based leader and innovator in natural medicines and ProThera is a specialist US nutraceutical company. The acquisitions mark an important milestone in establishing SFI as the leading global provider of clinically proven natural medicine.
With superior expertise, state-of-the-art manufacturing facilities and a complementary line of six natural medicine brands with significant growth potential, Ginsana helps SFI advance an extensive product portfolio and new product pipeline through a strong network of international distributors. These capabilities will enhance SFI’s Mission to give healthcare professionals and patients access to the best natural medicines supported by clinical studies. Ginsana will continue to market its products under the Ginsana brand name and manufacture world class natural medicines. The trademark rights of Pharmaton® remain at Pharmaton.
ProThera has over 50 years of formulation experience and a comprehensive product line of probiotics and dietary supplements distributed exclusively by healthcare providers. ProThera gives SFI entry into both the growing field of probiotics and the US market, further delivering on its mission to give healthcare providers and patients access to the best natural medicine supported by clinical studies.
“The parallel acquisitions of Ginsana and ProThera has not only extended our network and pipeline of natural medicine brands with great legacy, it allows us to enter into the attractive field of probiotics,” said SFI CEO, Nigel Pollard. LM
www.lawyer-monthly.com
ORCO-GSG
ProThera
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140